in one embodiment , this invention teaches a composition for the treatment of infectious diarrhea comprised of a therapeutically effective amount of berberine , with a blood anti - parasitic antimalarial agent , artemesinin , their pharmaceutically acceptable derivatives , salts , esters , chelates . most specifically , the artemesinin derivative is the salt of the succinic acid half ester derivative of dihydro - artemisinin known as artesunate . in this invention , the term berberine includes , but is not limited to , berberine alkaloid , berberine base , berberine hydrochloride , berberine , berberrubine , coreximine , tetrahydropalmatine , jatrorrhizine , 13 - hydroxyberberine chloride , coralyne , coralyne chloride , 7 , 8 - dihydro - 13 - methylberberine , berberine acetone , 13 - allylberberine , palmatine , 13 - benzylberberine , tetrahydroberberine , tetrahydroprotoberberine 8 - cyanodihydroberberine , dimeric protoberberine alkaloids , demethylated protoberberine alkaloids , quataternary protoberberine alkaloids , protoberberine and protoberberine alkaloids . in this invention , the salts of berberine , include berberine hydrochloride , berberine chloride , berberine sulfate , berberine tannate and other salts known to those versed in the art . in this invention , plant extracts containing berberine at a concentration of greater than 3 %, include , but are not limited to , the berberis family , berberis aristata , berberis aquifolllium , berberis vulgaris , berberis aetensis , coptis chinensis , chelidonium majus ( ukrain ), goldenseal ( hydrastis canadensis ), rhizoma coptidis , phellodendron chinense , aquilegia oxysepala , cortex phellodendra , huanglian jiedu decoction , san - huang - xie - xin - tang , xietianwu , gegen quinlian , and shizhu . in this invention , the terms ‘ artemisinin ’ and ‘ artesunate ’ will be u . s . pat . no . ______ to include artesunate , artemisinin , dihydroartemisinin , dihydroartemisinin hemisuccinate , dihydrodroartemisinin succinate , sodium artesunate , stabilized forms of artesunate , stabilized forms of sodium artesunate , dihydroartemisitene dimers ( u . s . pat . no . 7 , 098 , 242 ), amino - funtionalized 1 , 2 , 4 - trioxanes ( u . s . pat . no . 7 , 071 , 226 ), artemisinin endoperoxides ( u . s . pat . no . 6 , 984 , 640 ), spiro and dispiro 1 , 2 , 4 - trioxolane anti - malarials ( u . s . pat . no . 6 , 906 , 205 ), mixed steroidal 1 , 2 , 4 , 5 - tetraoxane compounds ( u . s . pat . no . 6 , 906 , 098 ), arteether ( u . s . pat . no . 6 , 750 , 356 ), substituted 1 , 2 , 4 - trioxanes ( u . s . pat . no . 6 , 737 , 438 ), artemisia annua extracts ( u . s . pat . no . 6 , 685 , 972 ), artemether ( u . s . pat . no . 6 , 683 , 193 , trioxane derivatives based on artemisinin ( u . s . pat . no . 6 , 649 , 647 ), trioxane dimer compounds ( u . s . pat . no . re38 , 117 ), conjugates of artelinic acid ( u . s . pat . no . 6 , 461 , 603 . ), arteethers from dihydroartemisinin ( u . s . pat . no . 6 , 346 , 631 ), artemisinine or artemisinene derivatives ( u . s . pat . no . 6 , 306 , 896 . ), c - 10 carbon substituted artemisinin - like trioxane compounds ( u . s . pat . no . 6 , 160 , 004 ). water - soluble trioxanes ( u . s . pat . no . 6 , 136 , 847 ), alpha arteether ( u . s . pat . no . 6 , 127 , 405 . ), artemisinin dimers ( u . s . pat . no . 5 , 856 , 351 ), (+)- deoxoarteminisinin and analogs of (+)- deoxoartemisinin ( u . s . pat . no . 5 , 225 , 562 ), and 10 - substituted ether derivatives of dihydroartemisinin ( u . s . pat . no . 5 , 225 , 427 ). specifically , the berberine , its pharmaceutically acceptable derivatives , salts , chelates and esters , is present in an amount of about 50 mg to about 1500 mg ; the artemisinin , its pharmaceutically acceptable derivatives , salts , chelates , and esters is present in an amount of about 1 mg to about 1500 mg ; and the loperamide , its pharmaceutically acceptable derivatives , salts , chelates , and esters is present in an amount of about 0 . 1 mg to about 200 mg . more specifically , the berberine , its pharmaceutically acceptable derivatives , salts , chelates and esters , is present in an amount of about 100 mg to about 1000 mg ; the artemisinin , its pharmaceutically acceptable derivatives , salts , chelates , and esters is present in an amount of about 20 mg to about 250 mg and the loperamide , its pharmaceutically acceptable derivatives , salts , chelates , and esters is present in an amount of about 0 . 5 mg to about 10 mg . more specifically , the berberine , its pharmaceutically acceptable derivatives , salts , chelates and esters , is present in an amount of about 200 mg to about 500 mg ; the artemisinin , its pharmaceutically acceptable derivatives , salts , chelates , and esters is present in an amount of about 40 mg to about 100 mg and the loperamide its pharmaceutically acceptable derivatives , salts , chelates , and esters is present in an amount of about 1 mg to about 3 mg . most specifically , berberine its pharmaceutically acceptable derivatives , salts , chelates and esters , is present in an amount of about 200 mg ; the artemisinin , its pharmaceutically acceptable derivatives , salts , chelates , and esters is present in an amount of about 50 mg and loperamide is present in an amount of about 2 mg . the composition may be present in dosage formulations selected from the group consisting of spray bottles , fast melt pill format , bursts , gel format , adhesive bandages , skin patches , gelcaps , softgels , gelatin capsules , vegetarian capsules , hard shell gelatin capsules , injections , intravenous solutions , topical creams , topical ointments , suppositories , or sublingual formulations . it may further comprise a therapeutically effective amount mefloquine for the treatment of malaria . in a specific embodiment of the invention , the berberine , artesunate and loperamide are packaged in a daily dispenser form with daily individual doses for a number of days of one day to ninety days , and the daily dispenser may be in the form of a travelers pack . also taught are methods for the treatment of travelers suffering from at least one of multiple parasitic , bacterial or viral infections simultaneously by the administration to a traveler of a therapeutically effective amount of the composition of berberine , artesunate and loperamide , their pharmaceutically acceptable derivatives , salts , esters , or chelates . the administration may be performed between one and three times per day , more specifically between two and three times per day . the method of treatment of a traveler may be fore the treatment of malaria , and the malaria may be chloroquine resistant . the same method of treatment may be used to treat mammals suffering from dysentery , diarrhea , or cholera . in another embodiment of the invention , the method of treatment is of a virus in a mammal such as dengue fever , hepatitis b , west nile virus , or human immunodeficiency virus ( hiv ). in the case of human immunodeficiency virus ( hiv ), the treatment may be adjunctive and the human immunodeficiency virus may be anti - retroviral resistant . in yet another embodiment of the invention , the treatment is of intestinal parasites in a mammal , including a tapeworm or tapeworms , or toxoplasmosis . while this invention has been particularly shown and described with references to preferred embodiments thereof , it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims . those skilled in the art will recognize or be able to ascertain using no more than routine experimentation , many equivalents to the specific embodiments of the invention described specifically herein . such equivalents are intended to be encompassed in the scope of the claims .
this invention relates to compositions and methods of combining berberine , artemisinin and loperamide or their derivatives in a therapeutic product for mammals suffering from malaria , diarrhea , travelers &# 39 ; diarrhea , dysentery , dengue fever , parasites , cholera and viruses by administration of a therapeutically effective amount of the composition .